Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
This trial is active, not recruiting.
|Start date||July 2003|
|Trial size||60 participants|
|Trial identifier||NCT00104689, CDR0000416120, EU-20500, FRE-FNCLCC-GERICO-02/0301|
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well giving capecitabine together with oxaliplatin works in treating older patients with metastatic colorectal cancer.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Caen, France||Centre Regional Francois Baclesse||no longer recruiting|
|Marseille, France||Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes||no longer recruiting|
|Paris, France||Hopital Europeen Georges Pompidou||no longer recruiting|
|Perigueux, France||Polyclinique Francheville||no longer recruiting|
|Reims, France||Institut Jean Godinot||no longer recruiting|
|Saint Cloud, France||Centre Rene Huguenin||no longer recruiting|
|Senlis, France||C.H. Senlis||no longer recruiting|
|Toulouse, France||Institut Claudius Regaud||no longer recruiting|
|Villejuif, France||Institut Gustave Roussy||no longer recruiting|
Efficacy in terms of stabilization or improvement by 1 point on Katz's Activities of Daily Living scale
Percentage of patients who receive the first 3 treatment courses at a lower dose and the percentage of patients who receive all 6 treatment courses at both lower and higher doses
Efficacy as defined in RECIST criteria
Male or female participants at least 70 years old.
DISEASE CHARACTERISTICS: - Diagnosis of colorectal adenocarcinoma - Metastatic disease - Requires first-line therapy for metastatic disease PATIENT CHARACTERISTICS: Age - Over 70 Performance status - Katz's Activities of Daily Living scale < 6 (≤ 6 for patients ≥ 80 years of age) Life expectancy - More than 3 months Hematopoietic - Absolute neutrophil count > 1,500/mm^3 - Platelet count > 100,000/mm^3 Hepatic - AST and ALT < 2 times normal (5 times normal if due to hepatic metastases) - Bilirubin < 2 times normal (5 times normal if due to hepatic metastases) Renal - Creatinine clearance > 30 mL/min Other - No clinical neuropathy PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - More than 6 months since prior adjuvant chemotherapy - No prior chemotherapy for metastatic disease Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified
|Official title||Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70|
|Description||OBJECTIVES: Primary - Determine the efficacy of capecitabine and oxaliplatin as first-line treatment, as defined by stabilization or improvement by 1 point on Katz's Activities of Daily Living scale, in older patients with metastatic colorectal adenocarcinoma. Secondary - Determine the toxicity of this regimen in these patients. - Determine the percentage of patients who receive the first 3 courses of this regimen (at lower doses) and the percentage of patients who receive all 6 courses of this regimen (at both lower and higher doses). - Determine efficacy of this regimen, as defined by RECIST criteria, in these patients. - Determine the pharmacokinetics of this regimen in these patients. OUTLINE: This is a multicenter, open-label, nonrandomized study. Patients receive oral capecitabine* once daily on days 1-14 and oxaliplatin* IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. NOTE: *The doses of both capecitabine and oxaliplatin are increased in courses 4-6 in the absence of unacceptable toxicity PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.|
Call for more information